Market Access

What AI Finds in Clinical Notes About Myasthenia Gravis That Claims Data Misses

HealthEconomics.com 2026 Pulse Check – March

What the New U.S.-UK Pharmaceuticals Deal Really Means for Pricing, Access, and Global Market Dynamics

From Questions to Outcomes: Real-World Impact of a Strong Value & Evidence Plan

5 Key Questions to Ask Before You Launch a Value Evidence Plan

Building Data-Driven Market Access Strategies for Commercial Success

ウェビナー

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

ウェビナー

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

ウェビナー

Network meta-analysis and its role in evidence-based decision-making

ウェビナー

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

ウェビナー

Market Access - Transforming BioTech Commercial Decisions?

ウェビナー

Insights from the 2024 Salary Survey Report by HealthEconomics.com

ウェビナー

Beyond Accelerated Approvals: External Control Arms

ウェビナー

Cell & Gene Therapies - Beginning with the End in Mind

ウェビナー

Tracking and Measuring Market Access Performance

ウェビナー

Medicare Part D: Price Negotiation Panel Discussion

ウェビナー

Impact of the 2023 CMS Prior Authorization Rule

ウェビナー

Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access

ウェビナー

Webcast: Taking the Complexity Out of Leveraging Health Plan Price Transparency Data

ウェビナー

Expediting drug product development and commercialization in global markets with global filing strategies

ウェビナー

How to Unlock Market Access & Pricing Potential of Orphan Drugs

ウェビナー

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

ウェビナー

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

ウェビナー

New Insights into ATMP Valuation and Outcomes-Based Pricing Experience

ウェビナー

Make Market Access Your Brand's Super Power - September 21st

ウェビナー

US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation - September 8th

ウェビナー

Informing Market Access Earlier in Clinical Development: Prospective RWE Research to Characterize Real World Patient Populations

ウェビナー

Become an expert & hone your skills for Pharma, Biotech, Medical & Diagnostic Device launches

ウェビナー

Marketplaces Drive Faster Science: HEOR, RWE & Market Access Sourcing

ウェビナー

Marketplaces Drive Faster Science: HEOR, RWE & Market Access Sourcing

ウェビナー

AMNOG impact on European countries?! Joint webinar with Medvance

ウェビナー

Value-Based Agreements - Are We Going to See More or Less of Them?

ウェビナー

Cutting Edge Conversations: Value, Access and Evidence - Biotech Market Access

ウェビナー

Cutting Edge Conversations: Value, Access and Evidence - Biotech Market Access

ウェビナー

Predicting Payer Uptake with Precision

ポッドキャスト

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap

ポッドキャスト

INsights & OUTcomes with Taylor Hirschberg

ポッドキャスト

Meeting the Resource Challenge - Why Biotechs Need a Different Kind of Partner

ポッドキャスト

INsights & OUTcomes with Matt McLoughlin

ポッドキャスト

INsights & OUTcomes with Rosa Willock

ポッドキャスト

INsights & OUTcomes with Chris O'Neill

ポッドキャスト

Podcast Q&A: EU HTA Joint Clinical Assessments

ポッドキャスト

Podcast Q&A: Medicare and Medicaid Services Market Pricing

ポッドキャスト

Podcast Q&A: Literature Reviews and Global Value Dossiers

ポッドキャスト

Podcast Q&A: Discussing Health Technology Assessment Agencies

ポッドキャスト

Podcast Q&A: Platforms and Models for Payer Insights and Evidence Generation

デモを見る

現代のライフサイエンスを支えるデジタル基盤

プロバイダー、ワークフロー、承認、コンプライアンス、データ、支出を一元管理できるインテリジェントなプラットフォームをご紹介します。複雑なプロジェクトをより迅速に、高い可視性と管理体制のもとで推進することが可能です。